The Wegovy wait continues
Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.
ISTH 2022 – Sanofi faces more fitusiran doubts
An investigator asks whether the haemophilia project, which has already been linked with toxicity concerns, should be given to elderly patients.
89bio’s home run fails to excite
The group gets a win in severe hypertriglyceridaemia, but a bigger readout in Nash awaits.
Big pharma’s key third-quarter data
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
ADA 2022 – Move over Mounjaro?
Lilly believes it has two promising new molecules for diabetes and obesity. But which to choose – and might toxicity yet scupper one or both?
